Payment overview · 2025
General Payments
$1,467.68
71 reported records · 18 companies
Healthcare provider profile · identity verified
Thomas Michael Helton, MD
Allopathic & Osteopathic Physicians|Family Medicine · MURFREESBORO, TN · NPI 1881624450
Verified facts
What the public records show
CMS Open Payments records show Thomas Michael Helton, MD received $1,467.68 in general payments during 2025 across 71 reported records.
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) accounted for 13.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 37 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Mounjaro, Nurtec Odt, Ozempic, Paxlovid, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 64 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 127 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 110 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Nurtec Odt by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $204.32 | 13.9% | 8 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $196.88 | 13.4% | 9 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $151.10 | 10.3% | 7 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $110.48 | 7.5% | 7 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $104.69 | 7.1% | 5 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $97.87 | 6.7% | 6 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $93.06 | 6.3% | 5 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $82.07 | 5.6% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $70.68 | 4.8% | 4 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $61.86 | 4.2% | 3 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $53.46 | 3.6% | 3 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $53.04 | 3.6% | 2 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $49.28 | 3.4% | 2 | 2025 |
| CeQur Corporation | Unresolved — no canonical attribution shown | $45.94 | 3.1% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $36.16 | 2.5% | 2 | 2025 |
| Seqirus USA Inc | Unresolved — no canonical attribution shown | $19.72 | 1.3% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $19.33 | 1.3% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $17.74 | 1.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,467.68 | 71 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $204.32 | 8 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $120.78 | 6 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $120.78 | 6 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $82.07 | 4 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $81.63 | 5 | 2025 |
Source payment records
|
|||||
| WaveWriter Alpha Prime 16 Normalized: wavewriter alpha prime 16 |
Device | Boston Scientific Corporation | $76.45 | 4 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $76.10 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $75.55 | 4 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $61.86 | 3 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $61.69 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $55.39 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $54.15 | 3 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $53.46 | 3 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $53.04 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $49.55 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $49.55 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $49.55 | 2 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $49.28 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $47.51 | 3 | 2025 |
Source payment records
|
|||||
| CeQur Simplicity Normalized: cequr simplicity |
Device | CeQur Corporation | $45.94 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $39.33 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $38.09 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $36.16 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $31.00 | 2 | 2025 |
Source payment records
|
|||||
| General - Erectile Dysfunction Normalized: general erectile dysfunction |
Device | Boston Scientific Corporation | $28.24 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $21.14 | 1 | 2025 |
Source payment records
|
|||||
| Fluad Normalized: fluad |
Biological | Seqirus USA Inc | $19.72 | 1 | 2025 |
Source payment records
|
|||||
| Flucelvax Normalized: flucelvax |
Biological | Seqirus USA Inc | $19.72 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $19.33 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $17.74 | 1 | 2025 |
Source payment records
|
|||||
| Saxenda Normalized: saxenda |
Drug | Novo Nordisk Inc | $17.51 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $17.51 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $16.53 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $16.37 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $16.24 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $16.24 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $14.46 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 26 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 127 | exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 18 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 37 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
33 | 13 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
64 | 12 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
37 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
63 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
127 | 24 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
110 | 29 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
18 | 18 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 728 | 242 |
| Levothyroxine Sodium | Levothyroxine Sodium | 583 | 169 |
| Alprazolam | Alprazolam | 429 | 68 |
| Lisinopril | Lisinopril | 414 | 130 |
| Gabapentin | Gabapentin | 408 | 109 |
| Pantoprazole Sodium | Pantoprazole Sodium | 393 | 129 |
| Amlodipine Besylate | Amlodipine Besylate | 349 | 106 |
| Losartan Potassium | Losartan Potassium | 328 | 99 |
| Omeprazole | Omeprazole | 319 | 97 |
| Metformin Hcl | Metformin Hcl | 318 | 100 |
| Simvastatin | Simvastatin | 274 | 80 |
| Furosemide | Furosemide | 263 | 93 |
| Tamsulosin Hcl | Tamsulosin Hcl | 232 | 71 |
| Meloxicam | Meloxicam | 214 | 73 |
| Trazodone Hcl | Trazodone Hcl | 210 | 61 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 209 | 67 |
| Potassium Chloride | Potassium Chloride | 198 | 59 |
| Allopurinol | Allopurinol | 186 | 52 |
| Metoprolol Tartrate | Metoprolol Tartrate | 169 | 60 |
| Hydrochlorothiazide | Hydrochlorothiazide | 167 | 58 |
| Metoprolol Succinate | Metoprolol Succinate | 166 | 56 |
| Pravastatin Sodium | Pravastatin Sodium | 165 | 50 |
| Carvedilol | Carvedilol | 159 | 54 |
| Glimepiride | Glimepiride | 156 | 51 |
| Sertraline Hcl | Sertraline Hcl | 149 | 41 |
| Donepezil Hcl | Donepezil Hcl | 148 | 38 |
| Fluticasone Propionate | Fluticasone Propionate | 138 | 55 |
| Duloxetine Hcl | Duloxetine Hcl | 135 | 38 |
| Pioglitazone Hcl | Pioglitazone Hcl | 131 | 41 |
| Diazepam | Diazepam | 130 | 24 |
| Hydralazine Hcl | Hydralazine Hcl | 128 | 42 |
| Ozempic | Semaglutide | 127 | 24 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 126 | 45 |
| Ondansetron Hcl | Ondansetron Hcl | 125 | 34 |
| Clonazepam | Clonazepam | 121 | 20 |
| Famotidine | Famotidine | 119 | 38 |
| Finasteride | Finasteride | 119 | 32 |
| Escitalopram Oxalate | Escitalopram Oxalate | 118 | 31 |
| Montelukast Sodium | Montelukast Sodium | 117 | 35 |
| Zolpidem Tartrate | Zolpidem Tartrate | 115 | 23 |
| Buspirone Hcl | Buspirone Hcl | 114 | 35 |
| Lorazepam | Lorazepam | 112 | 23 |
| Ropinirole Hcl | Ropinirole Hcl | 111 | 23 |
| Eliquis | Apixaban | 110 | 29 |
| Celecoxib | Celecoxib | 108 | 30 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 101 | 31 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 100 | 35 |
| Ezetimibe | Ezetimibe | 87 | 26 |
| Tizanidine Hcl | Tizanidine Hcl | 87 | 30 |
| Alendronate Sodium | Alendronate Sodium | 85 | 24 |
| Metformin Hcl Er | Metformin Hcl | 85 | 34 |
| Clopidogrel | Clopidogrel Bisulfate | 84 | 31 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 84 | 32 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 78 | 20 |
| Januvia | Sitagliptin Phosphate | 78 | 18 |
| Citalopram Hbr | Citalopram Hydrobromide | 77 | 21 |
| Doxycycline Hyclate | Doxycycline Hyclate | 76 | 43 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 76 | 38 |
| Baclofen | Baclofen | 74 | 15 |
| Chlorthalidone | Chlorthalidone | 74 | 24 |
| Bupropion Xl | Bupropion Hcl | 72 | 26 |
| Fluoxetine Hcl | Fluoxetine Hcl | 72 | 23 |
| Amitriptyline Hcl | Amitriptyline Hcl | 71 | 15 |
| Xarelto | Rivaroxaban | 71 | 17 |
| Meclizine Hcl | Meclizine Hcl | 70 | 20 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 70 | 34 |
| Atenolol | Atenolol | 69 | 21 |
| Primidone | Primidone | 68 | 20 |
| Warfarin Sodium | Warfarin Sodium | 68 | 21 |
| Estradiol | Estradiol | 66 | 20 |
| Pregabalin | Pregabalin | 66 | 19 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 64 | 46 |
| Synthroid | Levothyroxine Sodium | 64 | 12 |
| Jardiance | Empagliflozin | 63 | 15 |
| Prednisone | Prednisone | 62 | 29 |
| Spironolactone | Spironolactone | 61 | 21 |
| Cefdinir | Cefdinir | 60 | 53 |
| Quetiapine Fumarate | Quetiapine Fumarate | 60 | 18 |
| Memantine Hcl | Memantine Hcl | 59 | 13 |
| Diclofenac Sodium | Diclofenac Sodium | 58 | 20 |
| Ibuprofen | Ibuprofen | 58 | 18 |
| Tramadol Hcl | Tramadol Hcl | 58 | 20 |
| Clonidine Hcl | Clonidine Hcl | 56 | 24 |
| Azithromycin | Azithromycin | 53 | 48 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 51 | 19 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 50 | suppressed |
| Lovastatin | Lovastatin | 50 | 17 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 49 | 12 |
| Temazepam | Temazepam | 48 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 45 | 12 |
| Oxycodone Hcl | Oxycodone Hcl | 43 | 17 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 42 | suppressed |
| Fenofibrate | Fenofibrate | 42 | 14 |
| Mirtazapine | Mirtazapine | 42 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 42 | 12 |
| Benazepril Hcl | Benazepril Hcl | 41 | 12 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 40 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 40 | 12 |
| Tresiba Flextouch U-100 | Insulin Degludec | 40 | 11 |
| Valsartan | Valsartan | 40 | 13 |
| Methylprednisolone | Methylprednisolone | 39 | 35 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 38 | 11 |
| Metoclopramide Hcl | Metoclopramide Hcl | 38 | 11 |
| Midodrine Hcl | Midodrine Hcl | 38 | suppressed |
| Torsemide | Torsemide | 38 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 37 | 13 |
| Dicyclomine Hcl | Dicyclomine Hcl | 36 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 36 | 13 |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 34 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 34 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 33 | 14 |
| Fenofibrate | Fenofibrate Nanocrystallized | 33 | suppressed |
| Linzess | Linaclotide | 33 | 13 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 33 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 32 | 11 |
| Sucralfate | Sucralfate | 32 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 31 | suppressed |
| Topiramate | Topiramate | 31 | 13 |
| Trulicity | Dulaglutide | 31 | suppressed |
| Fluconazole | Fluconazole | 30 | 20 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 29 | 18 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 29 | suppressed |
| Levemir Flexpen | Insulin Detemir | 29 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 28 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 28 | 23 |
| Amoxicillin | Amoxicillin | 27 | 13 |
| Aripiprazole | Aripiprazole | 27 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 27 | suppressed |
| Irbesartan | Irbesartan | 27 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 27 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 26 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 26 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 26 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 25 | 12 |
| Colchicine | Colchicine | 25 | suppressed |
| Digoxin | Digoxin | 25 | suppressed |
| Glipizide | Glipizide | 25 | 13 |
| Sildenafil Citrate | Sildenafil Citrate | 25 | suppressed |
| Mounjaro | Tirzepatide | 24 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 24 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 23 | suppressed |
| Eszopiclone | Eszopiclone | 23 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 22 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 22 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 22 | suppressed |
| Gemfibrozil | Gemfibrozil | 22 | suppressed |
| Lamotrigine | Lamotrigine | 22 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 22 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 21 | 16 |
| Entresto | Sacubitril/Valsartan | 21 | suppressed |
| Nifedipine Er | Nifedipine | 21 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 21 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 21 | suppressed |
| Dutasteride | Dutasteride | 20 | suppressed |
| Humalog | Insulin Lispro | 20 | suppressed |
| Lansoprazole | Lansoprazole | 20 | suppressed |
| Myrbetriq | Mirabegron | 20 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 20 | suppressed |
| Zaleplon | Zaleplon | 20 | suppressed |
| Modafinil | Modafinil | 19 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 19 | suppressed |
| Ranolazine Er | Ranolazine | 19 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 18 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Glipizide Er | Glipizide | 18 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 18 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 18 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 18 | 18 |
| Premarin | Estrogens, Conjugated | 18 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 18 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 17 | suppressed |
| Novolog Flexpen | Insulin Aspart | 17 | suppressed |
| Nystatin | Nystatin | 17 | 13 |
| Raloxifene Hcl | Raloxifene Hcl | 17 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 16 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 16 | suppressed |
| Mupirocin | Mupirocin | 16 | suppressed |
| Ondansetron Odt | Ondansetron | 16 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 15 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 15 | suppressed |
| Levetiracetam | Levetiracetam | 14 | suppressed |
| Olanzapine | Olanzapine | 14 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 13 | 12 |
| Clindamycin Hcl | Clindamycin Hcl | 13 | 11 |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 13 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 13 | suppressed |
| Jantoven | Warfarin Sodium | 13 | suppressed |
| Klor-Con M20 | Potassium Chloride | 13 | suppressed |
| Novolin R Flexpen | Insulin Regular, Human | 13 | suppressed |
| Prempro | Estrogen,con/M-Progest Acet | 13 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 12 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 12 | suppressed |
| Brilinta | Ticagrelor | 12 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 12 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 12 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 12 | suppressed |
| Nitroglycerin | Nitroglycerin | 12 | suppressed |
| Piroxicam | Piroxicam | 12 | suppressed |
| Ramipril | Ramipril | 12 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 12 | suppressed |
| Acyclovir | Acyclovir | 11 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Carbamazepine | Carbamazepine | 11 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 11 | suppressed |
| Ketoconazole | Ketoconazole | 11 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 11 | suppressed |
| Metronidazole | Metronidazole | 11 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 11 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Niacin Er | Niacin | 11 | suppressed |
| Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Propafenone Hcl | Propafenone Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,467.68 · 71 records | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | ABRYSVO, AIRSUPRA, Auvelity, BREZTRI, CAPLYTA, COMIRNATY, CeQur Simplicity, EVENITY, FARXIGA, Fluad, Flucelvax, GEMTESA, General - Erectile Dysfunction, KISUNLA, Kerendia, LEQVIO, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, PAXLOVID, PREVNAR 20, PROLIA, QULIPTA, REPATHA, Rybelsus, Saxenda, TRELEGY ELLIPTA, TZIELD, UBRELVY, VRAYLAR, Veozah, WaveWriter Alpha Prime 16, Wegovy, XIFAXAN, ZAVZPRET, ZEPBOUND | 14 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error